Nasopharyngeal carcinoma.
Nasopharyngeal carcinoma (NPC) is endemic in southern China where genetic abnormalities and Epstein-Barr virus (EBV) infection are critical in the pathogenesis of the disease. Circulating EBV-DNA has been shown to improve prognostication and monitoring of NPC patients. Radiotherapy is the mainstay treatment for early disease and concurrent cisplatin/radiotherapy has been demonstrated to prolong survival in locoregionally advanced disease. Ongoing studies of targeting agents and immunotherapeutic approaches may further improve treatment results.
Chan
A T C
AT
Prince of Wales Hospital, Sir Y. K. Pao Cancer Center, Chinese University of Hong Kong, People's Republic of China. anthonytcchan@cuhk.edu.hk
Teo
P M L
PM
Johnson
P J
PJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000032:analysis*; D001707:Biopsy, Needle; D001918:Brachytherapy / Q000379:methods*; D002277:Carcinoma / Q000401:mortality / Q000473:pathology* / Q000628:therapy*; D002681:China / Q000453:epidemiology; D003131:Combined Modality Therapy; D004269:DNA, Bacterial / Q000032:analysis*; D005260:Female; D004854:Herpesvirus 4, Human / Q000302:isolation & purification*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D009303:Nasopharyngeal Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000628:therapy*; D009367:Neoplasm Staging; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D016019:Survival Analysis; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D004269:DNA, Bacterial